Study of Edecesertib in Participants With Cutaneous Lupus Erythematosus (CLE)

Key Inclusion Criteria:

• Either fulfill European League Against Rheumatism/American College of Rheumatology (EULAR/ACR) 2019 classification criteria for systemic lupus erythematosus (SLE)and/or have biopsy confirmed Cutaneous Lupus Erythematosus (CLE) at any time.

• Must have active CLE at screening and Day 1. Individuals with acute CLE (ACLE) musthave involvement of 2 distinct body areas.

• Cutaneous Lupus Erythematosus Disease Area and Severity Index activity - A (CLASI-A)score (excluding alopecia) of ≥ 8 and CLASI-A erythema score of ≥ 4 during screeningand on Day 1. Individuals with SLE must have Systemic Lupus Erythematosus DiseaseActivity Index 2000 (SLEDAI-2K) score of ≥ 4 at screening.

• Presence of at least 1 representative lupus skin lesion amenable to punch biopsy andindividual willingness to undergo skin punch biopsy at 2 time points.

• Must have documented prior intolerance or inadequate response at any time (perinvestigator judgement) to protocol-specified treatments.

• Topical corticosteroids or topical calcineurin inhibitors.

• Oral corticosteroids.

• Any other nonbiologic standard-of-care therapy, including, but not limited to:chloroquine, quinacrine, hydroxychloroquine, azathioprine, mycophenolatemofetil (MMF), leflunomide, dapsone, or methotrexate (MTX).

• Individuals willing to comply with all study visits and assessments.

Key Exclusion Criteria:

• Individuals with only chilblains lupus, lupus panniculitis, lupus tumidus and/orlocalized acute CLE involving only 1 distinct body area at screening and Day 1.

• Have highly active SLE (including but not limited to lupus nephritis,neuropsychiatric SLE, and/or vasculitis).

• Presence of active skin conditions other than cutaneous lupus that may interferewith assessing lupus-specific skin lesion(s) (eg, psoriasis, and/or drug-inducedlupus).

• Meet protocol-specified infection or lab criteria.

• Any active infection that is clinically significant (per investigatorjudgment).

• Any history of clinically significant liver disease.

• Significant cardiovascular disease.

Note: Other protocol defined Inclusion/Exclusion criteria may apply.